Edition:
United Kingdom

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

139.90USD
23 Apr 2019
Change (% chg)

$2.07 (+1.50%)
Prev Close
$137.83
Open
$137.42
Day's High
$140.84
Day's Low
$137.25
Volume
1,424,187
Avg. Vol
2,526,667
52-wk High
$148.97
52-wk Low
$118.62

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer... (more)

Overall

Beta: 0.80
Market Cap(Mil.): $357,562.41
Shares Outstanding(Mil.): 2,684.00
Dividend: 0.84
Yield (%): 2.52

Financials

  JNJ.N Industry Sector
P/E (TTM): 22.53 29.30 32.55
EPS (TTM): 5.91 -- --
ROI: 13.49 14.23 13.83
ROE: 22.63 15.46 15.25

UPDATE 1-Idorsia confirms 2019 spending plan as clinical trials "on track"

ZURICH, April 18 Swiss biotech Idorsia said on Thursday that all four clinical trials of its late-stage drug hopefuls were "on track" as it confirmed expectations of spending 570 million Swiss francs ($564 million) in the current year on the projects.

18 Apr 2019

US STOCKS-Wall St edges higher on generally positive earnings

* Netflix, IBM dip in after-hours trading after posting earnings

16 Apr 2019

US STOCKS-Wall St edges higher on generally upbeat earnings

* Indexes up: Dow 0.14 pct, S&P 0.02 pct, Nasdaq 0.32 pct (Updates to late afternoon, changes dateline, byline)

16 Apr 2019

US STOCKS-Wall St inches higher on tech boost, Johnson & Johnson earnings

* Indexes up: Dow 0.17%, S&P 0.17%, Nasdaq 0.40% (Changes comment, updates prices)

16 Apr 2019

Pharmaceuticals drive J&J to better-than-expected quarterly profit

Johnson & Johnson on Tuesday reported a first-quarter profit that exceeded Wall Street expectations on higher sales of its prescription medicines, including a double-digit increase for its psoriasis treatment Stelara, even as the company faces fierce competition for some of its other important drugs.

16 Apr 2019

Pharmaceuticals drive J&J to better-than-expected quarterly profit

Johnson & Johnson on Tuesday reported a first-quarter profit that exceeded Wall Street expectations on higher sales of its prescription medicines, including a double-digit increase for its psoriasis treatment Stelara, even as the company faces fierce competition for some of its other important drugs.

16 Apr 2019

UPDATE 3-Pharmaceuticals drive J&J to better-than-expected quarterly profit

April 16 Johnson & Johnson on Tuesday reported a first-quarter profit that exceeded Wall Street expectations on higher sales of its prescription medicines, including a double-digit increase for its psoriasis treatment Stelara, even as the company faces fierce competition for some of its other important drugs.

16 Apr 2019

US STOCKS-Wall St rises on tech boost, robust Johnson & Johnson earnings

* Indexes up: Dow 0.40%, S&P 0.31%, Nasdaq 0.36% (Updates prices to open)

16 Apr 2019

US STOCKS SNAPSHOT-Wall St opens higher after upbeat UnitedHealth, J&J results

April 16 U.S. stocks opened higher on Tuesday, taking the S&P 500 to less than a percent away from an all-time high, after better-than-expected results from healthcare giants UnitedHealth and Johnson & Johnson.

16 Apr 2019

US STOCKS-Wall St set to open higher on robust healthcare earnings

* Futures up: Dow 0.66%, S&P 0.37%, Nasdaq 0.43% (Adds comment, updates prices)

16 Apr 2019

Earnings vs. Estimates